683 Capital Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

683 Capital Management’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,321	Closed	-$331K	–	367
2022 Q1	$331K	Sell	10,321 -7,535	-42%	-$216K	0.02%	222
2021 Q4	$388K	Buy	+17,856	New	+$393K	0.01%	231
2021 Q1	–	Sell	-140,156	Closed	-$2.25M	–	268
2020 Q4	$2.25M	Hold	140,156	–	–	0.11%	96
2020 Q3	$1.5M	Hold	140,156	–	–	0.11%	89
2020 Q2	$1.7M	Hold	140,156	–	–	0.14%	87
2020 Q1	$1.38M	Buy	+140,156	New	+$1.84M	0.16%	82
2019 Q4	–	Sell	-81,874	Closed	-$1.28M	–	190
2019 Q3	$1.28M	Buy	81,874 +6,285	+8%	+$120K	0.14%	76
2019 Q2	$1.69M	Buy	75,589 +17,760	+31%	+$860K	0.15%	85
2019 Q1	$3.96M	Buy	57,829 +3,488	+6%	+$224K	0.36%	57
2018 Q4	$2.87M	Buy	54,341 +9,341	+21%	+$597K	0.17%	79
2018 Q3	$3.06M	Hold	45,000	–	–	0.2%	65
2018 Q2	$5.33M	Buy	45,000 +1,523	+4%	+$153K	0.36%	53
2018 Q1	$3.6M	Buy	43,477 +20,433	+89%	+$2.32M	0.32%	65
2017 Q4	$3.44M	Buy	+23,044	New	+$2.21M	0.29%	72

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

683 Capital Management's SRRA Position: Q2 2022 in Review

683 Capital Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 10,321 shares — an estimated $331K sold.

683 Capital Management first reported a position in SRRA in Q4 2017 and held it in 14 quarters. The position peaked at $5.33M in Q2 2018. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

683 Capital Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
683 Capital Management sold 10,321 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $331K.
683 Capital Management first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2017 and held it in 14 quarters.
683 Capital Management's Sierra Oncology, Inc. Common Stock position peaked at $5.33M in Q2 2018.
109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.